MISSION Rx Act
- Sponsor
- Rep. Vindman, Eugene Simon [D-VA-7]
- Committees
- Armed Services Committee (primary)
- Last action
- May 7, 2026
Bottom line
The MISSION Rx Act seeks to extend the benefits of Medicare's negotiated drug prices to military families, veterans, and federal procurement, potentially lowering out-of-pocket costs and government expenditures on prescription medications.
What it actually does
This bill, known as the MISSION Rx Act, aims to reduce prescription drug costs for military servicemembers, veterans, and federal agencies by linking their drug prices and cost-sharing amounts to the lower prices negotiated under the Medicare Drug Price Negotiation Program. Specifically, it caps TRICARE beneficiary cost-sharing and veteran copayments for 'selected drugs' at the Medicare Part D negotiated rates, and mandates that federal agencies procure these drugs at prices not exceeding the Medicare 'maximum fair price'.
Proponents argue
Proponents argue that servicemembers, veterans, and their families deserve access to the same lower drug prices achieved through federal negotiation programs as Medicare beneficiaries. They contend that this bill will reduce financial burdens on these groups, improve healthcare affordability, and ensure that the government is not overpaying for essential medications, thereby saving taxpayer dollars and enhancing the value of military and veteran benefits.
Opponents contend
Opponents might argue that extending Medicare's drug price negotiation framework to TRICARE and VA could disincentivize pharmaceutical innovation by reducing revenue for drug manufacturers, potentially leading to fewer new drugs or delayed access for these populations. They may also raise concerns about potential administrative complexities in aligning multiple federal healthcare programs and procurement systems.
The bill is short and relatively straightforward for those familiar with federal healthcare programs, allowing for quick comprehension of its core intent.
Section 2(a), amending Section 1074g of title 10, United States Code.
TRICARE Beneficiary Cost-Sharing Limit for Selected Drugs
This provision ensures that military servicemembers and their families covered by TRICARE will not pay more in cost-sharing for certain high-cost prescription drugs than what Medicare beneficiaries pay for the same drugs after prices have been negotiated under the Medicare Drug Price Negotiation Program. It directly links TRICARE out-of-pocket costs to the lower, negotiated Medicare rates.
Supporters argue
Supporters argue this provision ensures equitable access to affordable medications for military families, aligning their benefits with the cost savings achieved for other federal beneficiaries. It directly addresses the financial burden of prescription drugs on those who serve.
Critics contend
Critics might argue that this could create administrative burdens for TRICARE and potentially impact the formulary or availability of certain drugs if manufacturers are unwilling to participate under the new pricing structure, though the bill aims to align with existing federal programs.
Tradeoffs
Balances the goal of reducing out-of-pocket costs for military families against potential administrative complexities or industry concerns about expanded price controls.
Section 2(b), amending Section 1722A of title 38, United States Code.
Veteran Copayment Limit for Selected Drugs
This provision establishes that veterans receiving care through the Department of Veterans Affairs (VA) will not be required to pay more in copayments for "selected drugs" than Medicare beneficiaries pay for those same drugs under the Medicare Drug Price Negotiation Program. It aims to lower prescription drug costs for veterans by leveraging federal price negotiations.
Section 2(c), amending Section 8126 of title 38, United States Code.
Maximum Price for Selected Drugs in Federal Procurement
This provision mandates that when federal agencies, including the Department of Veterans Affairs, procure "selected drugs" from manufacturers, the maximum price they pay cannot exceed the "maximum fair price" established under the Medicare Drug Price Negotiation Program. This aims to ensure that the government itself benefits from the lowest negotiated prices for these specific drugs.
The bill repeatedly defines "selected drug" and "maximum fair price" by referencing specific sections of the Social Security Act (42 U.S.C. 1320f et seq.), which outlines the Medicare Drug Price Negotiation Program.
Sections 2(a)(2), 2(b)(e), 2(c)(3)(C), and 2(c)(3)(B)
Why it matters:This is standard legislative practice to avoid redundancy and ensure consistency with existing federal programs, rather than an attempt to obscure.
Case for: This approach ensures that the TRICARE, VA, and federal procurement programs automatically align with any changes or updates made to the Medicare Drug Price Negotiation Program, maintaining consistency across federal drug pricing policies.
Case against: A reader unfamiliar with the Social Security Act's drug pricing provisions would need to conduct additional research to fully grasp the scope and impact of this bill, potentially making it less accessible.
Estimated impact: This mechanism determines the specific drugs and price points affected by the bill, which could represent billions in savings or revenue impacts.
This subsection clarifies that the new federal procurement price caps apply to existing master agreements under 38 U.S.C. 8126 that are in effect on the date of enactment, as well as new agreements. It also specifies that if the Medicare Drug Price Negotiation Program terminates, the pricing for selected drugs under these master agreements would revert to the maximums under existing law.
Section 2(d)
Why it matters:This is standard legislative practice for specifying effective dates and contingencies, ensuring legal clarity for implementation and potential future policy shifts.
Case for: Applying the caps to existing agreements ensures immediate and broad impact, maximizing savings. The termination clause provides a clear legal framework for what happens if the underlying Medicare program is repealed or expires, preventing legal ambiguity.
Case against: Applying new price caps to existing contracts could be seen by manufacturers as a retroactive change to terms, potentially leading to legal challenges or disincentivizing future agreements, though the government's right to modify procurement terms is generally broad.
Estimated impact: This clause dictates the immediate and long-term financial impact of the procurement price caps, affecting potentially billions in federal drug spending.